Treating limited spread pancreatic cancer with local therapy
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a type of pancreatic cancer called pancreatic ductal adenocarcinoma.
- You have between 1 and 5 spots where the cancer has spread (metastases), and all of them can be treated with local therapies like radiation, surgery, or other procedures.
- You are generally well enough to have these treatments (ECOG score of 0-2).
- You cannot have cancer spread to the lining of your belly (peritoneal carcinomatosis) or fluid buildup in your chest or belly.
- You have not had more than 4 prior treatments for cancer that has spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a new treatment for people with advanced pancreatic cancer that has spread and is not removable by surgery, after standard treatments like chemotherapy no longer work. The goal is to see if this experimental therapy can help shrink tumors or slow the disease.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.